Analysts See $-0.05 EPS for NovaBay Pharmaceuticals, Inc. (NBY); Applied Dna Sciences (APDN)’s Sentiment Is 2.17

March 14, 2018 - By Darrin Black

Analysts expect NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) to report $-0.05 EPS on March, 20 after the close.They anticipate $0.08 EPS change or 61.54% from last quarter’s $-0.13 EPS. After having $-0.16 EPS previously, NovaBay Pharmaceuticals, Inc.’s analysts see -68.75% EPS growth. It closed at $3.15 lastly. It is down 7.90% since March 14, 2017 and is uptrending. It has underperformed by 8.80% the S&P500.

Applied DNA Sciences, Inc. provides biotechnology based security solutions for supply chain security, brand protection, and law enforcement applications in the United States, Europe, and Asia. The company has market cap of $47.58 million. The company’s supply chain security and product authentication solutions include SigNature DNA markers that are ingredients used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNature T DNA markers, which are tagging and authentication systems for use in brand protection efforts and raw material source compliance programs; and fiberTyping, a test of native cotton fiber. It currently has negative earnings. It also provides DNAnet, a DNA marker to link evidence and offenders to specific crime scenes; Beacon locked optical markers are encrypted mechanisms, which create a protected covert screening tool that can be adapted to packaging, security labels, and high–value assets through inks, varnishes, and coatings; and SigNify IF portable DNA reader that provides real-time authentication of in the field–DNA.

The stock increased 1.94% or $0.03 during the last trading session, reaching $1.58. About 24,790 shares traded. Applied DNA Sciences, Inc. (APDN) has declined 49.09% since March 14, 2017 and is downtrending. It has underperformed by 65.79% the S&P500.

Chase Investment Counsel Corp holds 0.12% of its portfolio in Applied DNA Sciences, Inc. for 77,563 shares. Benchmark Capital Advisors owns 50,000 shares or 0.11% of their US portfolio. Moreover, Dumont & Blake Investment Advisors Llc has 0.02% invested in the company for 18,412 shares. The California-based Reilly Financial Advisors Llc has invested 0.02% in the stock. Gluskin Sheff & Assoc Inc, a Ontario – Canada-based fund reported 20,000 shares.

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, makes, and markets anti-infective products for the eye care market in the United States. The company has market cap of $48.46 million. The Company’s commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. It currently has negative earnings. The firm has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: